TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Generating Evidence for a Support Package to Stabilize Youth Trajectories Out of Homelessness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between the ages of 16 and 26~* have obtained secure housing in a time period up to 12 months previously~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Transitional Case Management Only (Type: ACTIVE_COMPARATOR): Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
- Full HOP-C Service (Type: EXPERIMENTAL): Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a confirmed diagnosis of relapsing remitting MS per the 2010 McDonald criteria.~* Must have a known tetanus immunization history with most recent tetanus vaccination given 2 to 15 years prior to Screening and an anti-tetanus serum immunoglobulin titer at Screening that is less than or equal to one-half the upper limit of detection for the assay.~* Must have been on a stable approved dose of Tecfidera (240 mg twice daily \[BID\]) \[Group 1\] for ≥6 months or on a stable approved dose of a non-pegylated IFN (e.g., Avonex, Betaseron, Rebif, Extavia) \[Group 2\] for ≥3 months prior to Day 1.~Key Exclusion Criteria:~* Clinical relapse requiring treatment within 30 days prior to Day 1.~* Pneumococcal vaccination within 5 years prior to Screening.~* Previous exposure to meningococcal vaccines.~* Known hypersensitivity to Td, PPSV23, or MCV4 or their components.~NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Non-Pegylated IFN Treated Plus Vaccinations (Type: ACTIVE_COMPARATOR): Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL
- Tecfidera Treated Plus Vaccinations (Type: EXPERIMENTAL): Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who were not adequately controlled with a maximally tolerated daily dose of statin at stable dose for at least 4 weeks prior to the screening visit (Week -2).~Exclusion criteria:~* Age \< 18 or legal age of adulthood, whichever was greater~* Participants without established CHD or CHD risk equivalents~* LDL-C \<70 mg/dL (\<1.81 mmol/L) and participants with a history of documented cardiovascular disease~* LDL-C \<100 mg/dL (\<2.59 mmol/L) and participants without a history of documented CV disease~* Fasting serum triglycerides \>400 mg/dL (\>4.52 mmol/L)~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alirocumab 75 /up to 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged 18 90 years~* Subject must have a stable dialysis prescription for at least 28 days prior to start of Screening.~* Subject must have the most recent serum phosphate measurement, taken during the 28 days prior to the start of Screening, of ≥ 4.0 mg/dL and ≤ 8 mg/dL.~Exclusion Criteria:~* Subject's most recent historical pre-dialysis serum bicarbonate value within 14 days prior to the start of Screening (Visit 1) is \< 18 mg/dL.~* Subject has, in the opinion of the investigator, severe chronic lung disease and/or carbon dioxide retention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - PT20 400 mg tid (Type: EXPERIMENTAL): PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 2 - PT20 800 mg tid (Type: EXPERIMENTAL): PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 3 - PT20 1600 mg tid (Type: EXPERIMENTAL): PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 4 - PT20 3200 mg tid (Type: EXPERIMENTAL): PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 5 - Placebo tid (Type: PLACEBO_COMPARATOR): Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* previously untreated participants with cluster of differentiation 20 (CD20) positive B-cell chronic lymphocytic leukemia;~* participants with progressive Binet stage B, or C requiring therapy according to National Cancer Institute (NCI) criteria;~* Eastern Cooperative Oncology Group (ECOG) performance status \<=2.~Exclusion Criteria:~* previous treatment for Chronic Lymphocytic Leukaemia (CLL);~* known concomitant hematological malignancy;~* transformation to aggressive B-cell malignancy;~* history of severe cardiac disease;~* known hypersensitivity or anaphylactic reactions to murine antibodies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab plus Chlorambucil (Type: EXPERIMENTAL): Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documented congenital C1-INH deficiency~* Acute HAE attack~* Participation in base study CE1145_3001 (NCT00168103)~Key Exclusion Criteria:~* Acquired angioedema~* Treatment with any other investigational drug besides CE1145 in the last 30 days before study entry

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1 Esterase Inhibitor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ages eligible for study : 18 years to 74 years~* Genders eligible for study : Male and Female~* Diagnosed with T2DM~* Taking a stable dose of metformin monotherapy~* HbA1c levels of between ≥ 7.0% and ≤ 10.0%~* Females of childbearing potential who are not pregnant and agree to use a reliable method of birth control~* Written informed consent must be obtained~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Diagnosis of type 1 diabetes mellitus~* Uncontrolled diabetes defined as a FPG level of \> 240 mg/dL at screening~* A significant change in body weight in the 3 months before screening~* Any history of GI intolerance~* Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC~* Known history of acute or chronic pancreatitis~* A history of alcohol or drug abuse or drug addiction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- HM11260C (8 mg) (Type: EXPERIMENTAL): Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
- HM11260C (12 mg) (Type: EXPERIMENTAL): Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
- HM11260C (16 mg) (Type: EXPERIMENTAL): Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Monthly administration of placebo by subcutaneous injection for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female participants aged 9-45 years old and male participants aged 9-15 years old~* Participants agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes~* Not pregnant now (as demonstrated by a negative urine beta-Human Chorionic Gonadotropin (beta-HCG) test) for post-pubertal female participants

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): V501 (Gardasil®)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients who need total hip replacement were included in the initial sample. There was no age limit or restriction regarding gender for admission to the study.~Exclusion Criteria:~* Patients who underwent previous surgery in the same joint, evidence of joint infection, congenital or acquired coagulopathies, active intravascular coagulation, acute occlusive vasculopathy, hypersensitivity to TXA, chronic use of oral and steroid anticoagulants, history of severe or moderate allergy to plasma transfusion, chronic heart disease, malignant neoplasms and autoimmune diseases, patients who needed bone graft or underwent hip arthroplasty revision surgeries, and who did not consent to participate in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TXA (Type: EXPERIMENTAL): Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
- Control (Type: PLACEBO_COMPARATOR): This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline and Motivational Advice for Smokers With Substance Use Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of substance abuse or dependence by DSM-IV criteria~* Currently smoking at least 10 cigarettes per day for the past 6 months~Exclusion Criteria:~* Active psychosis or marked organic impairment according to medical records, or evidence of hallucinations or delusions~* Current use of any nicotine replacement, or other smoking cessation treatment~* Medical contraindications for NRT (including pregnancy, nursing, women not using birth control during heterosexual sex, history of unstable angina, history of severe congestive heart failure, uncontrolled hypertension, lung cancer, supplemental oxygen, allergy to adhesive, severe skin disease that requires treatment)~* Medical contraindications for VAR (including pregnancy, nursing, severe renal impairment by laboratory test, history of intolerance of varenicline, history of serious suicidal ideation or attempts in the past 5 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nicotine Replacement + PLA pill (Type: ACTIVE_COMPARATOR): Nicotine replacement treatment patch plus matched placebo pill
- Varenicline + PLA patch (Type: ACTIVE_COMPARATOR): Varenicline plus matched placebo patches containing no nicotine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed renal cell carcinoma that is metastatic or unresectable.~* If patients have measurable disease restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology.~* Patients must provide access to tissue blocks containing adequate tumor for interpretation and analysis.~* Patients must have measurable disease.~* Patients must have good performance status (ECOG 0 or 1; Karnofsky PS 100-80%).~* Patients must have adequate organ function.~* Patients must have no contraindication of vasopressor agents.~* Patients must be ≥ 18 years of age.~Exclusion Criteria:~* Patients who have received systemic therapy for metastatic disease.~* Patients with organ allografts.~* Patients who require or are likely to require systemic corticosteroid therapy for intercurrent illness.~* Patients with any significant medical disease other than the malignancy (e.g. COPD, patients with ascites or pleural effusions), which in the opinion of the investigator would significantly increase the risk of immunotherapy.~* Patients with a history of another malignancy within the past 5 years other than surgically cured non-melanoma skin cancer, carcinoma-in-situ or Stage I carcinoma of the cervix.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HD IL2 (Type: EXPERIMENTAL): Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* REGISTRATION-INCLUSION CRITERIA~* Age \>= 18 years and be diagnosed with cancer and receiving chemotherapy~* Ability to provide informed consent~* Willingness to complete questionnaires~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2~* One or more of the following nasal symptoms for which the patient reports they would appreciate treatment. Symptoms must have started after the initiation of systemic, antineoplastic therapies, be attributed to the systemic, antineoplastic therapies, and symptoms must be reported as being moderate (corresponding to a score of 2) or worse on a scale from mild (1) to very severe (4) on at least one of the items below.~  * Dryness~ * Discomfort/pain~ * Bleeding~ * Scabbing~ * Sores~Exclusion Criteria:~* REGISTRATION-EXCLUSION CRITERIA~* Predisposition to epistaxis prior to the initiation of cancer-directed therapy (more than once a month over the previous year)~* Planned initiation or continuation of any topical nasal treatment other than the studied nasal spray,(such as nasal steroids, Ayr nasal gel, Neosporin ointment or nasal administration of petroleum jelly). Taking Imitrex for migraines is acceptable~* Previous exposure to rose geranium in sesame oil nasal spray~* Concurrent upper respiratory tract infection~* History of allergic or other adverse reactions to sesame oil or essential rose geranium oil~* Any other reason that the study clinician or investigator feels precludes safe or appropriate inclusion in this study~* Vulnerable populations: pregnant women, prisoners, mentally handicapped~* RE-REGISTRATION~* The patient will be un-blinded and determined to have been on the saline arm, when initially randomized

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (rose geranium in sesame oil nasal spray) (Type: EXPERIMENTAL): Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.
- Arm B (isotonic nasal saline) (Type: PLACEBO_COMPARATOR): Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete